Introduction {#Sec1}
============

Neuroblastoma is the most common extracranial solid tumour of childhood. Arising from the neural crest, primary tumours can be localised in the adrenal glands or anywhere along the sympathetic side chain. Important prognostic factors are age, stage, MYCN amplification (MNA), loss of heterozygosity of chromosome 1p (1pLOH), chromosomal 11q aberration and DNA ploidy \[[@CR1]\]. Approximately 25 % of patients present with localised disease without distant metastases.

Treatment modality and intensity of treatment in patients with localised disease, stage 1--3 \[International Neuroblastoma Staging System (INSS)\], are based upon risk stratification and defined by age, stage and biological features. The prognosis is good and the majority of patients can be cured by surgery alone or by a combination of surgery and chemotherapy \[[@CR2]\].

If the primary tumour causes or is in danger of causing organ or respiratory dysfunction, as in paravertebral tumours with spinal cord compression, (urgent) treatment is needed. In these circumstances, volume reduction is necessary to reduce symptoms, usually with (neuro-) surgical resection (i.e. laminectomy). In these patients, treatment with chemotherapy is often recommended \[[@CR3]\]. However, as the prognosis of localised neuroblastoma is good, toxicity and late effects should be minimised. Targeted radiotherapy with ^131^I-metaiodobenzylguanidine (MIBG) is an effective treatment modality for neuroblastoma and rarely causes severe toxicity \[[@CR4], [@CR5]\].

The use of ^131^I-MIBG as initial therapy in patients with localised neuroblastoma has not been reported thus far. The aim of this retrospective study was to investigate the effect of ^131^I-MIBG therapy on resectability and outcome in patients with unresectable localised neuroblastoma causing or in danger of causing organ or respiratory dysfunction.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

In this retrospective cohort study we included all (21) neuroblastoma patients (0--18 years) diagnosed with INSS stage 1--3, treated initially with ^131^I-MIBG therapy, with inoperable MIBG-positive lesions that were causing or were in danger of causing organ dysfunction. The study was performed in the Emma Children's Hospital/Academic Medical Centre (EKZ/AMC) in Amsterdam between 1989 and 2008. Patients were treated with ^131^I-MIBG therapy if volume reduction was necessary to reduce symptoms of compromised organ or respiratory function and if tumour resection was not possible. Nine patients have been described before \[[@CR6]\].

Staging {#Sec4}
-------

The diagnostic workup consisted of imaging, analysis of urinary catecholamines, bone marrow biopsies/trephines, serum lactate dehydrogenase (LDH) and ferritin. Extension of the tumour was visualised with ultrasound (US), ^123^I-MIBG scintigraphy, computed tomography (CT) and/or magnetic resonance imaging (MRI). The diagnosis was confirmed histologically, with tissue obtained either by fine-needle aspiration, Tru-Cut biopsy or excisional biopsy. Staging was performed according to the INSS criteria \[[@CR7]\].

Treatment {#Sec5}
---------

Patients were treated with ^131^I-MIBG according to the protocol previously described by de Kraker et al. \[[@CR4]\]. Fixed doses were given; the first dose was either 200 or 150 mCi (7,400 or 5,550 MBq), and the second dose was lower, 150 or 100 mCi (5,550 or 3,700 MBq). Doses were adjusted based on age and stage. ^131^I-MIBG was infused slowly (100 mCi/h) with an interval of 4 weeks. Patients remained in radioprotective isolation until the exposure rate was less than 20 μSv/h, measured with a counter at a distance of 1 m from the patient \[[@CR4]\].

The parents were extensively informed about the nature and precise elements of the treatment and the differences from other strategies and consent was obtained prior to treatment.

Response {#Sec6}
--------

Response was graded according to the International Neuroblastoma Response Criteria (INRC) \[[@CR7]\]. Response of the tumour was evaluated 3--4 weeks after each course. Patients underwent multiple ^131^I-MIBG therapies if treatment was tolerated well, if ^131^I-MIBG uptake in the tumour was sufficient and if response was ongoing, but the tumour remained unresectable. Gross total resection was defined as removal of more than 95 % of the tumour. Partial resection was defined by the presence of macroscopic remnants.

Overall survival (OS) was measured as the time from start of treatment to death by any cause. Event-free survival (EFS) was defined as the time from start of treatment to a first event (progression, relapse or death).

Statistical analysis {#Sec7}
--------------------

OS and EFS were estimated by the Kaplan-Meier method. Patients were censored in the EFS analysis if they were lost to follow-up. The median follow-up was 8.5 years (range 0.4--19.6 years).

Results {#Sec8}
=======

Patients {#Sec9}
--------

Between 1989 and 2008, 21 patients (8 male, 13 female) with localised neuroblastoma (INSS stage 1--3) were treated with ^131^I-MIBG in the EKZ/AMC. The median age at diagnosis was 1.6 years (range 0--5.5 years); nine patients (43 %) were 1 year or younger (Table [1](#Tab1){ref-type="table"}, Supplementary Table [1](#MOESM1){ref-type="media"}). According to the INSS staging criteria, four neuroblastomas were classified as stage 1, three as stage 2 and 14 as stage 3. Tumours were localised in the abdomen in 11 patients. Other localisations were thoracic (*n* = 5), pelvic (*n* = 4) and the neck (*n* = 1).Table 1Patient characteristics at diagnosisNumber (%)*n*21Sex  Male8 (38)  Female13 (62)Age at diagnosis (years)  Median (range)1.6 (0--5.5)  ≤1 year9 (43)INSS stage  14 (19)  23 (14)  314 (67)Histology  Neuroblastoma17 (81)  Ganglioneuroblastoma4 (19)Localisation  Neck1 (5)  Thoracic5 (24)  Abdominal11 (52)  Pelvic4 (19)Intraspinal component7 (33)Genetic aberrations  MNA2/18  1pLOH1/18  Both1/18Urinary catecholamines  Elevated18/21  Normal3/21LDH  0--1 year (≥400 U/l)3/9  1--17 years (≥300 U/l)3/12Ferritin  ≥143 ng/ml4/18*n* number of patients, *INSS* International Neuroblastoma Staging System, *MNA* MYCN amplification, *1pLOH* chromosome 1p loss of heterozygosity, *LDH* lactate dehydrogenase

Seventeen patients had a neuroblastoma and four a ganglioneuroblastoma. Genetic aberrations were analysed in 18 patients: MNA was present in two tumours, 1pLOH in one and both aberrations in another patient. Urinary catecholamines were elevated in 18 patients; 3 patients with ganglioneuroblastoma had normal excretion (stage 1). LDH levels were elevated in 6 patients; ferritin was elevated in 4 of 18 patients.

^131^I-MIBG therapy {#Sec10}
-------------------

Primary resection of the tumour was not feasible in all patients and the tumour caused or was in danger of causing organ or respiratory dysfunction (Table [2](#Tab2){ref-type="table"}, Supplementary Table [2](#MOESM2){ref-type="media"}). Tumour extension into the spinal canal was the indication for ^131^I-MIBG therapy in seven patients. This caused neurological deficits in six patients. Indications for ^131^I-MIBG therapy in the remaining 14 patients were: compression of the trachea, close relationship to the kidney, encasement of major vessels, attachment to the crus of the diaphragm, partial intestinal obstruction or hydronephrosis.Table 2^131^I-MIBG therapy characteristicsNumber (%)*n*21Reasons for ^131^I-MIBG therapy  Compromised organ functions14 (67)  Intraspinal7 (33)Number of ^131^I-MIBG-infusions  13 (14)  215 (71)  31 (5)  40 (0)  51 (5)  60 (0)  71 (5)First ^131^I-MIBG-dose in mCi (Mbq)  50 (≈1,850)2 (10)  100 (≈3,700)4 (19)  150 (≈5,550)7 (33)  200 (≈7,400)6 (28)  Unknown2 (10)Second ^131^I-MIBG-dose in mCi (Mbq)  50 (≈1,850)1 (5)  100 (≈3,700)7 (39)  150 (≈5,550)7 (39)  200 (≈7,400)0  Unknown3 (17)*n* number of patients, *MIBG* metaiodobenzylguanidine, *mCi* millicurie, *MBq* megabecquerel

The median number of ^131^I-MIBG therapies given was two (range one to seven). Administered doses varied from 5.8 to 20.6 mCi/kg (median 13.4 mCi/kg) during the first treatment and from 5.9 to 16.3 mCi/kg (median 12.4 mCi/kg) during the second treatment. ^131^I-MIBG therapy was combined with topotecan in two patients according to the protocol that was used during that period.

Response {#Sec11}
--------

Delivered therapy and response are presented in Fig. [1](#Fig1){ref-type="fig"}. Treatment with solely ^131^I-MIBG therapy without additional chemotherapy (group A) in two patients resulted in complete response (CR) in one patient and a very good partial response (VGPR) in the other. This last patient was considered inoperable after ^131^I-MIBG therapy as the residual tumour was located against the crus of the diaphragm. CR was achieved in seven patients after ^131^I-MIBG therapy followed by surgery (group B). ^131^I-MIBG therapy, surgery and chemotherapy (group C) were given in three patients. One of them received two cycles of vincristine, etoposide, carboplatin and ifosfamide (VECI) after surgery because of 1pLOH and achieved CR. 1pLOH was not yet incorporated in the neuroblastoma risk stratification at that time, but increased risk was suspected based on preliminary data. In a second patient high-risk (HR) neuroblastoma (MNA and 1pLOH) was diagnosed and treated according to the HR protocol following ^131^I-MIBG therapy; subsequently CR was achieved. The third patient was treated with one VECI cycle while waiting for ^131^I-MIBG therapy; after ^131^I-MIBG therapy disease progressed and HR treatment was initiated. This patient died of progressive disease (PD).Fig. 1Flow chart response. *MIBG* metaiodobenzylguanidine, *chemo* chemotherapy, *CR* complete response, *VGPR* very good partial response, *PR* partial response, *MR* mixed response, *NR* no response, *PD* progressive disease

Nine patients had treatment prior to ^131^I-MIBG therapies. Surgery was the treatment preceding ^131^I-MIBG therapy (group D) in five patients. A laminotomy was performed in one patient because of tumour progression; this patient continued with ^131^I-MIBG therapy and achieved CR. Another patient underwent a laminectomy to relieve symptoms caused by an intraspinal tumour. The tumour recurred 4 months later and the patient was re-operated. A second relapse was treated with two cycles of ^131^I-MIBG therapy and CR was achieved. An emergency laminectomy and laminotomy were necessary in a third patient because of intraspinal extension of the tumour and this patient achieved CR after ^131^I-MIBG therapies. A presacral tumour in a fourth patient was treated with ^131^I-MIBG therapy after incomplete surgery. This patient achieved partial response (PR) after five cycles of ^131^I-MIBG therapy and the residual lesion remained stable during follow-up. The fifth patient was an infant at diagnosis and had a partial resection of a retroperitoneal presacral tumour in order to delay ^131^I-MIBG therapy. This patient achieved CR after ^131^I-MIBG therapy.

Both chemotherapy and surgery preceding ^131^I-MIBG therapy (group E) were applied in two patients. A laminotomy followed by a laminectomy and chemotherapy (CADO: cyclophosphamide, vincristine and doxorubicin) were performed in one patient. Because of PD during chemotherapy this patient received two cycles of ^131^I-MIBG therapy and subsequently achieved VGPR with a residual primary lesion that remained stable during follow-up. The other patient was treated with two cycles of vindesine, VP-16 and cisplatin followed by decompressive surgery in her home country preceding ^131^I-MIBG therapy achieving VGPR. Four months after the third course of ^131^I-MIBG therapy, she underwent a (macroscopic complete) surgical resection in the home country, despite the presence of surgical risk factors. As a complication of surgery, she became tetraplegic and died a few months later of an infection.

Modified cycles of chemotherapy were started before ^131^I-MIBG therapy (group F) in two patients. The first patient was treated in the home country with CADO before coming to our centre. The second patient was suspected to have a Wilms' tumour and was pretreated with vincristine and actinomycin; both achieved CR. No toxic deaths related to ^131^I-MIBG therapy occurred.

In conclusion, 16 of 21 patients achieved CR after treatment. Residual but stable disease (three VGPR, one PR) was achieved in four patients. One patient had PD and consequently died. The 10-year OS and EFS were both 90.5 % (Fig. [2](#Fig2){ref-type="fig"}). The median follow-up was 8.5 years (range 0.4--19.6 years).Fig. 2**a** OS: 10-year OS = 90.5 %, median follow-up = 8.5 years (range 0.4--19.6 years). Time since diagnosis: years. **b** EFS: 10-year EFS = 90.5 %, median follow-up = 8.5 years (range 0.4--19.6 years). Time since diagnosis: years

Discussion {#Sec12}
==========

We conclude that ^131^I-MIBG therapy is an effective treatment modality for unresectable localised neuroblastoma causing or in danger of causing organ or respiratory dysfunction. Of the 21 patients, 14 did not need chemotherapy.

In patients with localised neuroblastoma, without MNA or 1pLOH, observation or surgery is usually recommended \[[@CR8]\]. Since the start of ^131^I-MIBG therapy in the 1980s, several reports have described its efficacy and toxicity proven to be mild and infrequent \[[@CR4]\]. Phase I/II studies in patients with refractory or relapsed neuroblastoma showed a response rate of 10--56 %. Persistent thrombocytopenia was the main toxicity observed in these extensively pretreated patients \[[@CR9]\]. Because ^131^I-MIBG therapy was effective with limited toxicity, the patients with localised neuroblastoma in our cohort were treated with ^131^I-MIBG therapy, rather than chemotherapy when urgent treatment was indicated.

In this report, ^131^I-MIBG therapy proved to be a good alternative for chemotherapy for at least 14 of 21 (66.7 %) patients. Tumours regressed completely; residual lesions became resectable or remained stable. One exception was a HR tumour with MNA and 1pLOH that progressed during HR treatment and the patient eventually died.

The 10-year OS was 90.5 %. However, compared to other cohorts treated with chemotherapy and/or surgery, our cohort is small and heterogeneous. It included infants as well as older children with different risk profiles and different pre- and post-treatment modalities.

Since the prognosis of localised neuroblastoma is good, toxicity and late effects should be avoided if possible. Hence, Rubie et al. reported a 5-year OS of 99 % for a heterogeneous patient group of 120 infants. This group consisted of patients with and without threatening symptoms and different treatment strategies. The study stated that low-dose chemotherapy without anthracyclines was effective in 62 % of infants with an unresectable neuroblastoma and no MNA \[[@CR3]\]. No treatment-related deaths were observed. However, PD and recurrence occurred in 12 of 120 patients. Two patients in our cohort died. These deaths were not related to ^131^I-MIBG therapy but to progressive HR disease and to complications of surgery.

^131^I-MIBG therapy is mainly reported in patients with refractory or relapsed neuroblastoma. These patients have been treated with multiple preceding treatment modalities and therefore it is difficult to report which late effects are caused by ^131^I-MIBG therapy alone.

Thyroid toxicity is a known side effect of ^131^I-MIBG therapy. Although thyroid protection during ^131^I-MIBG therapy mostly prevents ^131^I thyroid uptake, late effects of ^131^I-MIBG therapy on thyroid function cannot be ruled out. Recently, our group reported two patients with differentiated thyroid carcinoma following ^131^I-MIBG therapy \[[@CR10]\]. These patients received adequate thyroid protection during ^131^I-MIBG therapy, and no ^131^I-MIBG uptake was seen in their thyroids on MIBG imaging. So, although no clear evidence is available thus far, patients should be checked regularly for thyroid problems after ^131^I-MIBG therapy. None of the patients described in this report developed a thyroid carcinoma.

In current protocols genetic aberrations such as MNA, 1pLOH and 11q aberration are included in risk classification systems \[[@CR1]\]. Three patients from our cohort were treated before genetic aberrations were implemented in treatment protocols. MNA and 1pLOH were present in one patient with a stage 3 neuroblastoma. This patient was eventually treated as a HR patient after three courses of ^131^I-MIBG therapy and is still alive 11 years after treatment. MNA was present in two other patients (stage 2 and 3). These two patients received two courses of ^131^I-MIBG therapy followed by a complete resection and are still alive after 12.2 and 7.5 years of follow-up respectively.

We conclude that ^131^I-MIBG therapy is an effective treatment modality for unresectable localised neuroblastoma causing or in danger of causing organ or respiratory dysfunction and offers a good alternative to chemotherapy if urgent treatment is needed. However, for the assessment of long-term toxicity, long-term follow-up for all patients treated with chemotherapy and/or with ^131^I-MIBG is needed.
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